TB-500 is marketed as thymosin beta-4, but it is a short fragment of it. The parent protein has small human trials. The fragment has none, and it carries doping-agent status with published detection methods.
Peptide Research
Published by Astra, which offers some of the treatments discussed. Educational, not medical advice.
Thymosin beta-4 is a 43-amino-acid protein found throughout human tissue and present at high concentration in platelets and wound fluid. Its primary cellular job is actin sequestration: it binds monomeric actin and regulates how quickly cells can assemble the internal filament scaffolding they use to change shape and migrate.
That function is unglamorous and central. Wound repair depends on cells crawling into a damaged area, and crawling depends on controlled actin dynamics. The literature describes thymosin beta-4 as an actin-sequestering protein that moonlights to repair injured tissues, a framing that captures how a housekeeping cytoskeletal protein turned out to have a regenerative signalling role.3
Its documented preclinical activities include promoting cell migration, supporting new blood vessel formation, reducing inflammation, and limiting scar tissue in models of injury across several organ systems. Reviews of its basic and clinical applications treat it as a genuine drug development candidate with a broad activity profile.4
This is real biology on a real molecule, and it is the foundation everything sold as TB-500 borrows credibility from.
TB-500 is not thymosin beta-4. It is a short synthetic peptide corresponding to an active region of the parent protein. The distinction is the spine of this guide because virtually every claim made for TB-500 is a claim demonstrated with thymosin beta-4.
The fragment exists because researchers asked a reasonable question: which part of this 43-residue protein carries the activity? Work defining the biological activities of thymosin beta-4 by active sites in short peptide sequences established that specific short stretches, including the actin-binding motif, retain measurable activity in laboratory assays.2 That is a legitimate finding, and it is what the entire TB-500 market is built on.
It is also a narrower finding than it is made to sound. Demonstrating that a fragment retains one activity in an assay does not establish that it reproduces the parent protein's full behaviour in a living organism. Proteins fold. Their activity depends on three-dimensional structure, on binding partners engaged by regions outside any single motif, and on stability and distribution once inside a body. A seven-residue peptide and a 43-residue protein have different half-lives, different tissue distribution, and different receptor engagement. Sometimes a fragment is a faithful minimal version of its parent. Sometimes it is a much weaker one. Sometimes it does something else entirely. Which of those applies to TB-500 in humans has not been determined.
This distinction gets erased constantly. Vendor pages headline TB-500 and then cite thymosin beta-4 research underneath, and the reader has no signal that the molecule changed between the headline and the citation.
Thymosin beta-4 has been in humans, in a small way, and the studies are worth describing accurately because they are the strongest evidence anywhere near this topic.
The best-designed is a randomised, placebo-controlled Phase II trial of thymosin beta-4 ophthalmic solution for dry eye, conducted using the controlled adverse environment model.6 That is a proper trial design: randomised, placebo-controlled, in patients, with a defined endpoint. It is also Phase II, meaning small and exploratory, and it studied an eye drop for dry eye.
The other human line is dermal wound healing. Work on the regenerative peptide thymosin beta-4 reported accelerated dermal healing in preclinical animal models and in patients, covering wounds including chronic non-healing ulcers.5 Again: real human exposure, small numbers, specific wound populations, topical application to an open wound.
Notice what these trials share. Both delivered the full parent protein. Both used local administration to an accessible surface, an eye or an open wound, rather than systemic injection. Both were small and early-phase. Neither studied athletic recovery, tendon or ligament repair, muscle injury, or joint healing, which are the uses TB-500 is actually sold for. Neither tested the fragment.
So the accurate statement is that thymosin beta-4 has preliminary human evidence for two specific local applications, and TB-500 has none for anything.
TB-500 is a prohibited substance in competitive sport, and unlike most of the peptides in this library, its detection has been worked out in published analytical chemistry.
Doping control analysis of TB-500, described explicitly as a synthetic version of an active region of thymosin beta-4, has been established in equine urine and plasma using liquid chromatography-mass spectrometry.1 That paper's framing is itself instructive: the analytical chemistry literature defines TB-500 as a fragment of thymosin beta-4, exactly the distinction the sales literature blurs.
The equine origin is not incidental either. TB-500 entered widespread use in horse racing before it became a human consumer product, which is where much of the anecdotal reputation for tendon and soft-tissue healing originates. Racing anecdote is not clinical evidence, and horses are not people.
Practically, an athlete subject to testing should treat TB-500 as detectable and prohibited. The assays exist and are published. This guide takes no position on sport policy and offers no reassurance about detection windows or testing practice, because any such reassurance would be unsupportable.
TB-500 is not an FDA-approved drug. It is also not currently legal to compound in the United States, so a licensed US compounding pharmacy cannot prepare it against a prescription.
The FDA's Pharmacy Compounding Advisory Committee reviewed several of these peptides in July 2026. PCAC is advisory and no rule has been issued. Sources describing a decision, an outcome, or an availability timeline for TB-500 are describing something that has not been published.
Supply therefore comes through research-chemical vendors selling lyophilised vials labelled for research use only. Those vendors are not licensed pharmacies and are not inspected as such. Identity, purity, and sterility are seller claims. For an injectable reconstituted at home, sterility failures produce abscesses and bloodstream infections regardless of whether the peptide inside has any activity.
There is an additional wrinkle specific to this molecule. Because TB-500 and thymosin beta-4 are used interchangeably in marketing, buyers frequently cannot tell which one a vial is supposed to contain, and there is no independent verification of either.
One question resolves most of them: is this claim about thymosin beta-4 or about TB-500? Ask it of every citation and the marketing collapses cleanly into its parts.
Actin sequestration and tissue repair biology: parent protein.3 Broad regenerative activity profile and development potential: parent protein.4 Randomised placebo-controlled dry eye trial: parent protein, as an eye drop.6 Accelerated dermal wound healing in patients: parent protein, applied to wounds.5 Activity retained in short peptide sequences: laboratory active-site mapping, which is the fragment's actual evidentiary basis.2 Detection in doping control: the fragment, in horses.1
The soft-tissue healing use case that drives nearly all TB-500 sales appears nowhere in the human column. There is no randomised trial of TB-500 for tendon injury, ligament repair, muscle strain, or joint recovery in people. There is preclinical plausibility inherited from a related molecule, an active-site rationale, and a large volume of anecdote from horse racing and online forums.
None of this means the fragment is inert. It means the question of whether it does anything useful in a human being has never been properly asked, and answering it with the parent protein's trials is a substitution the evidence does not permit.
Every human trial cited to sell TB-500 studied a different molecule. That is not a nuance in the evidence. It is the whole of it.
Astra Editorial, reviewing the thymosin beta-4 literature
No. Thymosin beta-4 is a 43-amino-acid protein. TB-500 is a short synthetic peptide corresponding to an active region of it. The human trial evidence belongs to the full protein, not the fragment.
No. The human studies commonly cited, including a randomised placebo-controlled Phase II dry eye trial and dermal wound healing work in patients, used thymosin beta-4 itself, delivered locally as an eye drop or to a wound.
Yes. Doping control assays for TB-500 using liquid chromatography-mass spectrometry have been published. Athletes subject to testing should treat it as a detectable prohibited substance.
No. TB-500 is not FDA-approved and is not currently available for compounding in the United States. Product sold online comes from research-chemical suppliers outside pharmacy licensing and manufacturing oversight.
TB-500 is not sold at Astra. It is not FDA-approved, and it is not currently available for compounding in the United States, so there is no legitimate prescription pathway to it today. It is also a prohibited substance in tested sport with published detection assays. Keep reading in the Astra Learn library, and we will publish an update if human trial data or the regulatory picture changes.
This guide is educational and is not medical advice. Compounded medications are not FDA-approved. Speak with a licensed physician about your own care.